GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Synthetic organic
Comment: DF-003 is an orally hbioactive alpha kinase 1 (ALPK1) inhibitor [1].
The rare genetic autoinflammatory condition known as retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and headache (ROSAH) syndrome is caused by activating mutations in ALPK1. DF-003 was designed as a disease modifying therapy to directly target the hyperactive ALPK1. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Fan J, Liu D, Ming Z, Yan C, Dang H, Pan Y, Wei X, Zhao Z, Wang W, Zhang S et al.. (2025)
Discovery of a selective alpha-kinase 1 inhibitor for the rare genetic disease ROSAH syndrome. Nat Commun, 16 (1): 8251. [PMID:40925900] |
|
2. FDA.
Orphan Drug Designations and Approvals. Accessed on 29/04/2026. Modified on 29/04/2026. www.accessdata.fda.gov, www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=976923 |